Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 178

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer

Open access
Kwak, Taekyoung, Wang, Fang, Deng, Hui, Condamine, Thomas, Kumar, Vinit, Perego, Michela, Kossenkov, Andrew, Montaner, Luis J., Xu, Xiaowei, Xu, Wei, Zheng, Cathy, Schuchter, Lynn M., Amaravadi, Ravi K., Mitchell, Tara C., Karakousis, Giorgos C., Mulligan, Charles, Nam, Brian, Masters, Gregory, Hockstein, Neil, Bennett, Joseph, Nefedova, Yulia, Gabrilovich, Dmitry I. · 2020 · Cell Reports

Abstract

Here, we report that functional heterogeneity of macrophages in cancer could be determined by the nature of their precursors: monocytes (Mons) and monocytic myeloid-derived suppressor cells (M-MDSCs). Macrophages that are differentiated from M-MDSCs, but not from Mons, are immune suppressive, with a genomic profile matching that of M-MDSCs. Immune-suppressive activity of M-MDSC-derived macrophages is dependent on the persistent expression of S100A9 protein in these cells. S100A9 also promotes M2 polarization of macrophages. Tissue-resident- and Mon-derived macrophages lack expression of this protein. S100A9-dependent immune-suppressive activity of macrophages involves transcription factor C/EBPβ. The presence of S100A9-positive macrophages in tumor tissues is associated with shorter survival in patients with head and neck cancer and poor response to PD-1 antibody treatment in patients with metastatic melanoma. Thus, this study reveals the pathway of the development of immune-suppressive macrophages and suggests an approach to their selective targeting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.celrep.2020.108571

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 53

  1. Arts, 2018, BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity, Cell Host Microbe, 23, 89, 10.1016/j.chom.2017.12.010 · DOI · Paper page
  2. Austermann, 2018, S100 proteins in rheumatic diseases, Nat. Rev. Rheumatol., 14, 528, 10.1038/s41584-018-0058-9 · DOI
  3. Baratelli, 2005, Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells, J. Immunol., 175, 1483, 10.4049/jimmunol.175.3.1483 · DOI · Paper page
  4. Bekkering, 2018, Metabolic Induction of Trained Immunity through the Mevalonate Pathway, Cell, 172, 135, 10.1016/j.cell.2017.11.025 · DOI · Paper page
  5. Bronte, 2019, Deciphering Macrophage and Monocyte Code to Stratify Human Breast Cancer Patients, Cancer Cell, 35, 538, 10.1016/j.ccell.2019.03.010 · DOI
  6. Cassetta, 2018, Targeting macrophages: therapeutic approaches in cancer, Nat. Rev., 17, 887
  7. Cheng, 2008, Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein, J. Exp. Med., 205, 2235, 10.1084/jem.20080132 · DOI · Paper page
  8. Chouaib, 1985, Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulation of transferrin receptor expression, J. Immunol., 135, 1172, 10.4049/jimmunol.135.2.1172 · DOI · Paper page
  9. Christ, 2018, Western Diet Triggers NLRP3-Dependent Innate Immune Reprogramming, Cell, 172, 162, 10.1016/j.cell.2017.12.013 · DOI · Paper page
  10. Condamine, 2015, Regulation of tumor metastasis by myeloid-derived suppressor cells, Annu. Rev. Med., 66, 97, 10.1146/annurev-med-051013-052304 · DOI · Paper page
  11. Cortez-Retamozo, 2012, Origins of tumor-associated macrophages and neutrophils, Proc. Natl. Acad. Sci. USA, 109, 2491, 10.1073/pnas.1113744109 · DOI · Paper page
  12. Fujita, 2011, COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells, Cancer Res., 71, 2664, 10.1158/0008-5472.CAN-10-3055 · DOI · Paper page
  13. Gabrilovich, 2017, Myeloid-Derived Suppressor Cells, Cancer Immunol. Res., 5, 3, 10.1158/2326-6066.CIR-16-0297 · DOI · Paper page
  14. Ghavami, 2009, S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis, Eur. J. Pharmacol., 625, 73, 10.1016/j.ejphar.2009.08.044 · DOI
  15. Goodwin, 1983, Regulation of the immune response by prostaglandins, J. Clin. Immunol., 3, 295, 10.1007/BF00915791 · DOI · Paper page
  16. He, 2018, Transitory presence of myeloid-derived suppressor cells in neonates is critical for control of inflammation, Nat. Med., 24, 224, 10.1038/nm.4467 · DOI · Paper page
  17. Kato, 1998, Transgenic mouse model for skin malignant melanoma, Oncogene, 17, 1885, 10.1038/sj.onc.1202077 · DOI · Paper page
  18. Kerkhoff, 2005, The arachidonic acid-binding protein S100A8/A9 promotes NADPH oxidase activation by interaction with p67phox and Rac-2, FASEB J., 19, 467, 10.1096/fj.04-2377fje · DOI · Paper page
  19. Kielbassa, 2019, Understanding the Origin and Diversity of Macrophages to Tailor Their Targeting in Solid Cancers, Front. Immunol., 10, 2215, 10.3389/fimmu.2019.02215 · DOI
  20. Kocieda, 2012, Prostaglandin E2-induced IL-23p19 subunit is regulated by cAMP-responsive element-binding protein and C/AATT enhancer-binding protein β in bone marrow-derived dendritic cells, J. Biol. Chem., 287, 36922, 10.1074/jbc.M112.402958 · DOI
  21. Kumar, 2016, CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation, Immunity, 44, 303, 10.1016/j.immuni.2016.01.014 · DOI · Paper page
  22. Langmead, 2012, Fast gapped-read alignment with Bowtie 2, Nat. Methods, 9, 357, 10.1038/nmeth.1923 · DOI · Paper page
  23. Laoui, 2014, Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population, Cancer Res., 74, 24, 10.1158/0008-5472.CAN-13-1196 · DOI · Paper page
  24. Lim, 2016, Targeting the CCL2-CCR2 signaling axis in cancer metastasis, Oncotarget, 7, 28697, 10.18632/oncotarget.7376 · DOI · Paper page
  25. Lu, 2011, Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice, J. Clin. Invest., 121, 4015, 10.1172/JCI45862 · DOI · Paper page
  26. Manitz, 2003, Loss of S100A9 (MRP14) results in reduced interleukin-8-induced CD11b surface expression, a polarized microfilament system, and diminished responsiveness to chemoattractants in vitro, Mol. Cell. Biol., 23, 1034, 10.1128/MCB.23.3.1034-1043.2003 · DOI · Paper page
  27. Mantovani, 2010, Macrophages, innate immunity and cancer: balance, tolerance, and diversity, Curr. Opin. Immunol., 22, 231, 10.1016/j.coi.2010.01.009 · DOI · Paper page
  28. Mao, 2014, Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity, Clin. Cancer Res., 20, 4096, 10.1158/1078-0432.CCR-14-0635 · DOI · Paper page
  29. Marigo, 2010, Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor, Immunity, 32, 790, 10.1016/j.immuni.2010.05.010 · DOI · Paper page
  30. Mastio, 2019, Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs, J. Exp. Med., 216, 2150, 10.1084/jem.20181952 · DOI · Paper page
  31. Meyer, 2011, Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model, Proc. Natl. Acad. Sci. USA, 108, 17111, 10.1073/pnas.1108121108 · DOI · Paper page
  32. Milutinović, 2016, Immune memory in invertebrates, Semin. Immunol., 28, 328, 10.1016/j.smim.2016.05.004 · DOI · Paper page
  33. Murray, 2014, Macrophage activation and polarization: nomenclature and experimental guidelines, Immunity, 41, 14, 10.1016/j.immuni.2014.06.008 · DOI · Paper page
  34. Na, 2015, Endogenous prostaglandin E2 potentiates anti-inflammatory phenotype of macrophage through the CREB-C/EBP-β cascade, Eur. J. Immunol., 45, 2661, 10.1002/eji.201545471 · DOI
  35. Nakanishi, 2013, Multifaceted roles of PGE2 in inflammation and cancer, Semin. Immunopathol., 35, 123, 10.1007/s00281-012-0342-8 · DOI · Paper page
  36. Nerlov, 2007, The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control, Trends Cell Biol., 17, 318, 10.1016/j.tcb.2007.07.004 · DOI · Paper page
  37. Obermajer, 2011, Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells, Blood, 118, 5498, 10.1182/blood-2011-07-365825 · DOI · Paper page
  38. Oppenheim, 2005, Alarmins: chemotactic activators of immune responses, Curr. Opin. Immunol., 17, 359, 10.1016/j.coi.2005.06.002 · DOI · Paper page
  39. Ortiz, 2014, Myeloid-derived suppressor cells in the development of lung cancer, Cancer Immunol. Res., 2, 50, 10.1158/2326-6066.CIR-13-0129 · DOI
  40. Ortiz, 2015, Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells, J. Exp. Med., 212, 351, 10.1084/jem.20140835 · DOI
  41. Pathria, 2019, Targeting Tumor-Associated Macrophages in Cancer, Trends Immunol., 40, 310, 10.1016/j.it.2019.02.003 · DOI · Paper page
  42. Pinto, 2019, The Two Faces of Tumor-Associated Macrophages and Their Clinical Significance in Colorectal Cancer, Front. Immunol., 10, 1875, 10.3389/fimmu.2019.01875 · DOI · Paper page
  43. Ricciotti, 2013, COX-2, the dominant source of prostacyclin, Proc. Natl. Acad. Sci. USA, 110, E183, 10.1073/pnas.1219073110 · DOI
  44. Rodriguez, 2005, Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma, J. Exp. Med., 202, 931, 10.1084/jem.20050715 · DOI · Paper page
  45. Sajti, 2020, Transcriptomic and epigenetic mechanisms underlying myeloid diversity in the lung, Nat. Immunol., 21, 221, 10.1038/s41590-019-0582-z · DOI
  46. Sanford, 2013, Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis, Clin. Cancer Res., 19, 3404, 10.1158/1078-0432.CCR-13-0525 · DOI · Paper page
  47. Sinha, 2007, Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells, Cancer Res., 67, 4507, 10.1158/0008-5472.CAN-06-4174 · DOI · Paper page
  48. Song, 2018, Immune Training Unlocks Innate Potential, Cell, 172, 3, 10.1016/j.cell.2017.12.034 · DOI
  49. Veglia, 2018, Myeloid-derived suppressor cells coming of age, Nat. Immunol., 19, 108, 10.1038/s41590-017-0022-x · DOI · Paper page
  50. Veltman, 2010, COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function, BMC Cancer, 10, 464, 10.1186/1471-2407-10-464 · DOI · Paper page
  51. Wagner, 2019, Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies, J. Immunother. Cancer, 7, 343, 10.1186/s40425-019-0828-1 · DOI
  52. Wang, 2018, Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: A meta-analysis of 40 studies, OncoImmunology, 7, e1494113, 10.1080/2162402X.2018.1494113 · DOI
  53. Zhao, 2012, S100A9 a new marker for monocytic human myeloid-derived suppressor cells, Immunology, 136, 176, 10.1111/j.1365-2567.2012.03566.x · DOI · Paper page

Cited by

Metadata

Authors
Kwak, T., Wang, F., Deng, H., Condamine, T., Kumar, V., Perego, M., Kossenkov, A., Montaner, L. J., Xu, X., Xu, W., Zheng, C., Schuchter, L. M., Amaravadi, R. K., Mitchell, T. C., Karakousis, G. C., Mulligan, C., Nam, B., Masters, G., Hockstein, N., Bennett, J., Nefedova, Y., & Gabrilovich, D. I.
Venue
Cell Reports
Publisher
Elsevier BV
Published
2020-12
Volume
33
Issue
13
Pages
108571
ISSN
2211-1247 (ISSN-L)
OpenAlex
W3116206322
Cited by
178
References
18
FWCI
6.58
Type
journal article
Language
en
Open access
gold
Licence
Funders
National Cancer Institute

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.